Pharmasset, Inc. (VRUS) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-91.19M
Depreciation and amortization
Non-cash stock compensation	7.81M
Non-cash interest expense	166K
Amounts due from collaboration partner, prepaid expenses and other assets	-2.83M
Accounts payable	666K
Accrued expenses	1.6M
Deferred rent	1K
Deferred revenue	-898K
Net cash used in operating activities	-84.06M
Purchase of equipment
Net cash used in investing activities	-868K
Proceeds from exercise of stock options	10.15M
Principal payments on long-term debt	-9.19M
Proceeds from issuance of common stock, net of issuance costs of $6,211 and $7,111 during 2011 and 2010, respectively	123.35M
Net cash provided by financing activities	124.31M
Net increase in cash and cash equivalents	39.37M
Cash and cash equivalents - Beginning of period	127.08M
Cash and cash equivalents - End of period	166.46M
Interest	892K
Value of warrants exercised by converting warrants into shares of common stock ("net issuance method")
Disposal of equipment (fully depreciated)	117K

Entities mentioned with VRUS

View All Entities